Vitamin D Insufficiency is a Frequent Finding in Pediatric and Adult Patients with Sickle Cell Disease and Correlates with Markers of Cell Turnover

Winters AC1, Kethman W2, Kruse-Jarres R3 and Kanter J4

1Cincinnati Children’s Hospital, Burnet Ave, Cincinnati, OH 45229, USA
2Stanford University, Serra Mall, Stanford, CA 94305, USA
3Tulane University, St Charles Ave, New Orleans, LA 70118, USA
4Medical University of South Carolina, Charleston, SC, USA

Corresponding author: Julie Kanter, Director, Sickle Cell Disease Research, MUSC, 135 Rutledge Avenue, MSC 558, Charleston, SC, 29425, USA, Tel: (843) 876-8483; E-mail: kanter@musc.edu

Rec Date: April 14, 2014, Acc Date: Jun 16, 2014, Pub Date: Jun 18, 2014

Abstract

Vitamin D insufficiency affects 33%-78% of children and 60-100% of adults with sickle cell disease (SCD). There are no previous reports demonstrating a correlation between vitamin D insufficiency and cell turnover in patients with SCD. We hypothesized that vitamin D insufficiency was prevalent in our SCD population (ages 0-60 years) and would correlate with reticulocyte counts in these patients. We performed a retrospective cross-sectional review of the medical records of 194 patients (ages up to 60 years) with SCD to evaluate their 25-hydroxyvitamin D levels as a function of red blood cell turnover, patient’s age, number of pain crises, SCD genotype, and Hydroxyurea therapy. Vitamin D insufficiency was present in 88% of children and 96% of adults in our patient cohort. Serum 25-OH vitamin D levels correlated significantly with both age and reticulocyte counts in multiple regression analysis. Furthermore, pediatric HbSS patients had significantly lower 25-OH vitamin D levels than HbSC patients. No significant correlation was found between vitamin D levels and number of pain crises. Based on these findings, vitamin D insufficiency is a function of overall disease severity as manifested by the correlation with reticulocytosis.

Keywords: Sickle cell disease; Vitamin D deficiency; Reticulocytosis; Nutrition

Introduction

Vitamin D insufficiency is an established phenomenon in patients with Sickle Cell Disease (SCD) between 33 and 78 percent of children and between 60 and 100 percent of adults with SCD has been found to have low serum levels of 25-hydroxyvitamin D [1-7] the form that best reflects total body levels of the vitamin [8]. Although a large portion of the population has been described as having low levels of vitamin D [9,10], individuals with SCD are at higher risk for vitamin D deficiency than their healthy counterparts [1,2,7]. One research group at Children’s Hospital of Philadelphia found that a significantly higher percentage of pediatric SCD patients met the criteria for vitamin D deficiency than healthy African-American children in that city (33% vs. 9%) [1]. The same researchers also found that children with SCD as a population had substantially lower mean serum 25-OH vitamin D levels than a control population of African-American children [2]. Studies of adults with SCD have cited data from the National Health and Nutrition Examination Survey (NHANES), which reveal an overall prevalence of vitamin D deficiency in the U.S. general population of 2-6% more than tenfold lower than the prevalence in adult SCD patients [7,9]. These studies clearly demonstrate an association between vitamin D insufficiency and individuals with sickle cell disease but do not explore the causality or ramifications of this insufficiency.

The body’s supply of vitamin D is synthesized in the skin, a process that requires exposure to sunlight [8]. One theory suggests that SCD patients develop vitamin D deficiency as a result of limited access to sunlight [1,7], presumably secondary to more severe illness restricting mobility and frequent hospitalizations. To our knowledge only one study has investigated the possible link between number of vaso-occlusive crises and vitamin D deficiency, and no such correlation was found [3]. Vitamin D can also be absorbed in the small intestine from dietary sources or, more commonly, from supplements, and is stored in adipose tissue [8]. Poor nutrition and/or fat malabsorption have also been postulated to play a role in vitamin D insufficiency in SCD [2,7], although no studies evaluating these factors in vitamin D-deficient SCD patients have been published. We hypothesize that vitamin D deficiency in patients with sickle cell disease correlates with rate of red blood cell turnover, as defined by reticulocytosis, a marker of hyper hemolytic sickle cell disease.

Methods

Patients with SCD of all ages are followed by the Sickle Cell Center of Southern Louisiana at Tulane University. Vitamin D assessment (25-OH vitamin D measurement) is included during their routine, comprehensive assessments.

Patient inclusion

To be included in this retrospective study, persons had to have a known diagnosis of SCD (HbSS, HbSC, and HbSβ0+ or HbSβ0). Patients of all ages (up to 60 years) were included. Patients had to have a vitamin D level drawn within the 2 years prior to data collection before they were started on supplemental therapy.
Patient exclusion

Patients were excluded if they had received a blood transfusion within one month of assessment. Patients were not included if acutely ill (vitamin D levels were only assessed at baseline state of health). Patients prescribed vitamin D supplements were not included. Expedited IRB approval was obtained from Tulane University’s Biomedical Institutional Review Board, as all data were collected retrospectively and were de-identified prior to analysis. No informed consent was required or obtained.

Vitamin D measurements

Serum testing of vitamin D was performed by an immunochemiluminometric assay (ICMA) performed on a DiaSorin LIAISON® instrument. Vitamin D levels are routinely obtained at patients’ comprehensive visits (every 3-6 months). Only the initial measurement of serum 25-OH vitamin D was used in the analysis (i.e. not repeated measurements) since most patients were prescribed supplementation after the initial level was obtained in clinic.

Retrospective chart review

Patient records were accessed retrospectively to collect the following additional demographic data: patients’ age, baseline laboratory data including hemoglobin, reticulocyte count, and lactate dehydrogenase (LDH). Data were also collected to assess the utilization of health care resources and clinical burden of disease over a 12-month period (either 2009 or 2010) including number of emergency department visits, hospital admissions, and sickle cell day hospital visits with primary diagnosis of vaso-occlusive crisis. Average length of stay (LOS) for these visits was calculated. In pediatric patients (<21 years of age), it was also noted whether the patient had a history of avascular necrosis (AVN) and/or concurrent treatment with Hydroxyurea (HU).

Statistical analysis

Descriptive statistical analysis was used to characterize the patient population. ANOVA was used to assess the differences between group means (laboratory and demographic variables) and linear regression was performed to determine the significance between those variables determined to be significant in multivariate analysis. Regression analysis was used to assess each of the designated demographic variables including hemoglobin, reticulocyte count, LDH, hospital days/12 month period, number of ED visits, and genotype.

Results

Patient demographics

Data were collected on 90 pediatric patients and 104 adult patients with SCD, illustrated in Table 1. Average age of pediatric patients was 10.2 ± 5.6 years (up to 21 years), with 68% HbSS, 25% HbSC, and 7% HbSβ+. Average age of adult patients was 33.3 ± 10.5 years (21-60 years), with 71% HbSS, 19% HbSC, and 10% HbSβ+ or HbSβ0.

| Variable                | Pediatric Patients | Adult Patients |
|-------------------------|--------------------|----------------|
| Number (n)              | 90                 | 104            |
| Age (years)             | 10.2 ± 5.6         | 33.3 ± 10.5    |
| Genotype                |                    |                |
| SS                      | 61 (68%)           | 74 (71%)       |
| SC                      | 23 (25%)           | 20 (19%)       |
| SB(0 or +)              | 6 (7%)             | 10 (10%)       |
| Vitamin D (ng/mL)       | 17.2 ± 9.5         | 13.6 ± 7.9     |
| <11                     | 29 (32%)           | 51 (49%)       |
| 11-30                   | 50 (56%)           | 49 (47%)       |
| >30                     | 11 (12%)           | 4 (4%)         |
| Baseline Hgb            | 9.2 ± 1.3          | 9.1 ± 1.8      |
| Reticulocyte count (%)  | 8.3 ± 4.9          | 8.2 ± 4.7**    |
| LDH                     | 414 ± 159**        | 375 ± 205**    |
| Hydroxyurea (HU)        |                    |                |
| Yes                     | 24 (24 HbSS)       | not evaluated  |
| No                      | 66 (37 HbSS)       | not evaluated  |

Values for indicated fields are expressed as means ± SD. All other values reflect number of patients, with percentages in parentheses.
correlation between vitamin D levels and either frequency of healthcare encounters for pain or average length of stay per encounter in the adult population (all p-values ≥ 0.4). Likewise, no association was made between vitamin D levels and frequency of healthcare encounters for vaso-occlusive crisis in pediatric patients (p-values ≥ 0.4).

Hydroxyurea

Hydroxyurea (HU) has been studied extensively as a disease-modifying agent in sickle cell disease. It is known to increase levels of Fetalhemoglobin (HbF), to decrease leukocyte and reticulocyte counts, and likely to decrease the “stickiness” of red blood cells and the vascular endothelium [11]. This translates clinically into overall decreases in healthcare encounters for vaso-occlusive crises, decreased lengths of stay during hospitalization, and decreased utilization of opioid analgesics, for those patients who are maintained on HU [12,13]. Despite these advantages, when serum 25-OH vitamin D levels in pediatric patients who were prescribed HU (n=24, all HbSS) were compared with levels in HbSS patients who were not on HU (n=37), there was no statistically significant difference in the mean 25-OH vitamin D levels between the two groups (p=0.333).

Discussion

To the authors’ knowledge, this is the only study to assess vitamin D deficiency across the age spectrum in sickle cell disease. Several previous articles have presented the high prevalence of vitamin D deficiency in SCD; however, this was the first paper to evaluate the role of cell turnover in predicting vitamin D deficiency. Reticulocyte count provides a measure of red blood cell turnover in sickle cell patients, and can provide physicians with information about both the degree of sickling in a patient and the capacity of the bone marrow to compensate for loss of erythrocytes. Recent evidence suggests that reticulocyte count can be a predictor of long-term outcomes in sickle cell disease, as well. Several studies have validated reticulocytosis as a marker for both pulmonary hypertension and cerebrovascular accident [14-17]. However, this is the first study to identify the association of high hemolysis with vitamin D insufficiency. This finding is useful moving forward in determining the cause of vitamin D deficiency in this patient population. It appears from this study that the increased activity of the bone marrow in high hemolytic patients with SCD may prevent sufficient vitamin D absorption.
Prevalence of vitamin D insufficiency in this cohort

For this analysis, vitamin D deficiency was defined as 25-OH vitamin D<11 ng/ml (<27.5 nM) and vitamin D insufficiency defined as 11-30 ng/ml (27.5-75 nM). These cutoffs have been used in a previous study of vitamin D levels in SCD patients [1], and were chosen based on population cohort studies of vitamin D in bone health [18,19]. All patients noted to have vitamin D insufficiency or deficiency were treated with weekly vitamin D supplementation (50,000 IU) per week until levels were sufficient. They were then maintained on 1,000 IU daily.

Healthcare utilization

Vaso-occlusive crisis is the primary reason for which patients of all ages with SCD are admitted to the hospital. Patients who are frequently admitted may be more sedentary or more likely to engage in indoor activities. Without sunlight, vitamin D cannot be synthesized in the skin, and the individual is left without adequate stores of the vitamin [8]. However, the amount of healthcare utilization including total number of days spent inpatient did not correlate with vitamin D insufficiency. In the pediatric cohort, the degree of vitamin D insufficiency did correlate significantly with average length of stay in the hospital (p=0.006). However, these patients also tend to be more hemolytic. Thus, given the demonstrated correlations between low serum 25-OH vitamin D and reticulocytosis and SCD genotype, the relationship between the disease process and vitamin D status is likely to be far more complex.

Vitamin D and bone health

In the past, vitamin D has been studied primarily in the context of bone health. Osteopenia is well established in the context of sickle cell disease [4,5]. Bone density scans are not routinely obtained on asymptomatic sickle cell patients in our practice; therefore, as this study was retrospective in design, we have no data on the prevalence of osteopenia in this patient cohort, nor can we comment on a correlation between osteopenia and vitamin D levels in this population. However, despite the 88% of pediatric patients in this study with vitamin D insufficiency, we note <5% of children with SCD who have previously documented Avascular Necrosis (AVN).

Limitations

There are several limitations to this study. The sample size is relatively small, thus limiting the statistical power of our findings. Due to the retrospective nature of the study, we also lacked a control population for the prevalence of vitamin D insufficiency in our community. However, a study of healthy preschool-aged African-American children from low-income families in Atlanta, GA found that 26% had 25-OH vitamin D levels less than 20 ng/mL (50 nM) [20] compared to 46% of our patients less than 5 years old with similar 25-OH vitamin D levels. A study out of Boston, MA reported a 36% prevalence of vitamin D deficiency-defined as 25-OH vitamin D levels <=15 ng/mL (<=37.4 nM) in healthy African American adolescents ages 11-18 years [21]. By comparison, 61% of patients aged 11-18 years old in our cohort had 25-OH vitamin D levels <=15 ng/mL (<=37.4 nM), despite residing at lower latitudes than the Boston study subjects. Therefore, it is reasonable to conclude that African-American children and adolescents with SCD are at increased risk for vitamin D deficiency than their healthy counterparts. Good control data for vitamin D levels in adult SCD patients is not as forthcoming. Data from National Health and Nutrition Examination Surveys (NHANES) suggest that between 14 and 44% of African-American adults have 25-OH vitamin D levels less than 10 ng/mL (25 nM), while only 2-6% are vitamin D sufficient (25-OH vitamin D >30 ng/mL or >75 n M) [9]. These percentiles closely match those from the adult SCD patients in the current study. However, a significant number of African-American individuals included in the NHANES data likely have sickle cell disease, making it impossible to utilize this data as a true historical control.

Conclusions

This study suggests that vitamin D insufficiency in patients with sickle cell disease may be related to the disease process itself. Specifically, the data support our hypothesis that low vitamin D levels correlate with reticulocytosis in SCD patients. It should be emphasized that the data presented here is merely correlative. Any cause-effect relationships that exist between inadequate levels of vitamin D and various measures of sickle cell disease severity must be identified.
through prospective interventional studies. Further, the clinical ramifications of this association, as well as the potential impact of vitamin D replacement on clinical outcomes of SCD, are topics for future study. Further investigations will also focus on dietary issues in SCD patients and on the possibility of differential vitamin D metabolism in these individuals. Through improved understanding of the causes and effects of vitamin D deficiency and insufficiency in the context of sickle cell disease, we can begin to predict whether vitamin D replacement as an adjunct therapy could improve the quality of life of SCD patients.

References

1. Rovner AJ, Stallings VA, Kawchak DA, Schall JI, Ohene-Frempong K, et al. (2008) High risk of vitamin D deficiency in children with sickle cell disease. J Am Diet Assoc 108: 1512-1516.

2. Buison AM, Kawchak DA, Schall JI, Ohene-Frempong K, Stallings VA, et al. (2004) Low vitamin D status in children with sickle cell disease. J Pediatr 145:622-627.

3. Osunkwo I, Hodgman EI, Cherry K, Dampier C, Eckman J, et al. (2011) Vitamin D deficiency and chronic pain in sickle cell disease. Br J Haematol 153: 538-540.

4. Chapelon E, Garabedian M, Brousse V, Souberbielle JC, Bresson JL, et al. (2009) Osteopenia and vitamin D deficiency in children with sickle cell disease. Eur J Haematol 83: 572-578.

5. Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP (2006) Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer 47: 901-906.

6. Adewoye AH, Chen TC, Ma Q, McMahon L, Mathieu J, et al. (2008) Sickle cell bone disease: response to vitamin D and calcium. Am J Hematol 83: 271-274.

7. Goodman BM 3rd, Artz N, Radford B, Chen IA (2010) Prevalence of vitamin D deficiency in adults with sickle cell disease. J Natl Med Assoc 102: 332-335.

8. Rosen CJ (2011) Clinical practice. Vitamin D insufficiency. N Engl J Med 364: 248-254.

9. Ginde AA, Liu MC, Camargo CA Jr (2009) Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 169: 626-632.

10. Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML (2009) Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 124: e362-e370.

11. Hebbel RP, Vercellotti G, Nath KA (2009) A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemoprophylaxis. Cardiovasc Hematol Drug Targets 9: 271-292.

12. Ballas S, Bauserman R, McCarthy W, Castro O, Smith W, et al. (2010) Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage 40: 870-882.

13. Candrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, et al. (2011) Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 86: 273-277.

14. Liem RI, Young LT, Thompson AA (2007) Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica 92: 1549-1552.

15. Pashankar FD, Carbonella J, Bassy-Asaad A, Friedman A (2008) Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics 121: 777-782.

16. Minniti C, Sable C, Campbell A, Rana S, Ensing G, (2009) Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica 94: 340-347.

17. Silva CM, Giovani P, Viana MB (2011) High reticulocyte count is an independent risk factor for cerebrovascular disease in children with sickle cell anemia. Pediatr Blood Cancer 56: 116-121.

18. Priemel M, von Domarus C, Klatte T, Kessler S, Schlie J, et al. (2010) Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Min Res 25: 305-312.

19. van Schoor NM, Visser M, Pluijm SM, Kuchuk N, Smit JH, et al. (2008) Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone 42: 260-266.

20. Cole CR, Grant FK, Tangpricha V, Swaby-Ellis ED, Smith JL, et al. (2010) 25-hydroxyvitamin D status of healthy, low-income, minority children in Atlanta, Georgia. Pediatrics 125: 633-639.

21. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ (2004) Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 158: 331-337.